Rethinking Ophthalmology
LATEST NEWS
Our Treatment Candidates
Diabetic Macula
Edema
~37 million people worldwide suffer from diabetic macular edema (DME)1,2, a leading cause of preventable blindness in working-age adults3.
OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, has the potential to become the first non-invasive treatment for DME and aim to address unmet medical needs for earlier treatment intervention and the treatment of suboptimal responders to anti-VEGF therapies.
OCS-01
OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, has the potential to become the first non-invasive treatment for DME and aim to address unmet medical needs for earlier treatment intervention and the treatment of suboptimal responders to anti-VEGF therapies.
Dry Eye Disease
>110 million people worldwide4 suffer from dry eye disease (DED), a multifactorial disease with a dissatisfied and heterogeneous patient population5.
OCS-02 (licaminlimab), an anti-TNFα eye drop candidate specifically designed to treat ocular inflammation, has the potential to transform the treatment paradigm of DED with a precision medicine strategy.
OCS-02
OCS-02 (licaminlimab), an anti-TNFα eye drop candidate specifically designed to treat ocular inflammation, has the potential to transform the treatment paradigm of DED with a precision medicine strategy.
Acute Optic
Neuritis
Up to 8 in 100,000 people worldwide suffer from acute optic neuritis (AON)6, a rare disease that can lead to permanent visual impairment mostly occurring in young adults.
OCS-05, a serum glucocorticoid kinase-2 (SGK-2) activator, has the potential to become a novel neuroprotective therapy for acute optic neuritis and other neuro-ophthalmic diseases.
OCS-05
OCS-05, a serum glucocorticoid kinase-2 (SGK-2) activator, has the potential to become a novel neuroprotective therapy for acute optic neuritis and other neuro-ophthalmic diseases.
OCS-01, OCS-02 and OCS-05 are investigational drugs and have not received regulatory approval for commercial use in any country.
Our Relentless Focus to Understand and Address Key Unmet Medical Needs in Eye Diseases
We drive innovation from a patient perspective and focus on eye diseases where high unmet medical needs remain. As we rethink ophthalmology, we undertake a disciplined and rigorous process to understand the biology behind eye diseases to develop transformative innovations that have the potential to make a real difference in patients’ lives.
Our Purpose Is to Drive Innovation to Save Sight And Improve Eye Care
Meet The Team Dedicated to Making A Real Difference In Patients’ Lives
Our innovative pipeline has the potential to address key unmet medical needs in ophthalmology, including for DME and DED, with treatments that are highly differentiated, which have the potential to completely change the current treatment paradigms. I am confident that our dedication to developing transformative innovations, our patient-centric approach, and our focus on operational excellence will eventually make a real difference in patients’ lives.